Across TCGA pan-cancer cohorts, ICE1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ICE1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ICE1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ICE1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
UCEC, LUAD, and BLCA are the cancer types where ICE1 Mutation most reproducibly stratifies survival.